Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

22. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) 29023213 2017 12 08 2017 12 08 1527-7755 35 35 2017 Dec 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two (...) Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 3924-3933 10.1200/JCO.2017.74.3062 Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results

EvidenceUpdates2017

23. Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab CASE REPORT Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab Kazuaki Okamura 1 , Yuichi Fukuda 1 , Hiroshi Soda 1 , Daiki Ogawara 1 , Keisuke Iwasaki 2 , Shinichiro Fuchi 2 , Takayuki Suyama 1 , Masataka Yoshida 1 , Tatsuhiko Harada 1 , Minoru Fukuda 3,4 & Hiroshi Mukae 3 (...) , in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD-1 + immune cells and regulatory T cells in the tumor, in addition to predominant in?ltration of CD8 + cells and macrophages. Our ?ndings suggest that the presence of a small number of PD-1 + immune cells and regulatory T cells should be investigated as candidate therapeutic biomarkers. Introduction Pulmonary pleomorphic carcinoma (PPC), an aggressive subtype of lung cancer, has been

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

26. Nivolumab (Opdivo) in combination with platinum

Nivolumab (Opdivo) in combination with platinum Nivolumab (Opdivo) in combination with platinum ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Nivolumab (Opdivo) in combination with platinum October 2017 Technology Description: Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth (...) of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer an additional treatment option for patients with advanced NSCLC who currently have failed to respond to standard of care chemotherapy alone. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed to your free download Where are you based? England Wales, Scotland, N.Ireland Other country

NIHR Innovation Observatory2017

27. Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab

Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab 29027754 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. 164-166 10.1111/1759-7714.12522 Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis (...) , China. Xin Tao T 0000-0001-5868-6189 Department of Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China. eng Case Reports Journal Article 2017 10 13 Singapore Thorac Cancer 101531441 1759-7706 0 Antibodies, Monoclonal 0 Quinazolines 31YO63LBSN nivolumab 41UD74L59M afatinib IM N Engl J Med. 2015 Jul 9;373(2):123-35 26028407 Lancet Oncol. 2015 Aug;16(8):897-907 26156651 J Clin Oncol. 2016 Sep 1;34(25):2980-7 27354485 Aged Antibodies, Monoclonal pharmacology therapeutic

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

28. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments (...) for these patients. We assessed the efficacy and safety of nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1), in patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial done at 49 clinical sites in Japan, South Korea, and Taiwan, eligible patients (aged ≥20 years with unresectable advanced or recurrent gastric

Lancet2017

29. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature

Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature 29067215 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. e000217 10.1136/esmoopen-2017-000217 Immune checkpoint blockade including programmed cell death 1 pathway inhibition with agents (...) such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved survival rates even in metastatic, often multiply pretreated settings. Although targeted in nature and generally well-tolerated compared with conventional anticancer treatments, these agents are often linked to a newly emerged group of adverse reactions, referred to as immune-related adverse events, which can also affect endocrine organs. This is a case report of a patient who received nivolumab

ESMO open2017 Full Text: Link to full Text with Trip Pro

30. [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V]

[Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to §35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma (...) of the head and neck) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB

Health Technology Assessment (HTA) Database.2017

31. Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line

Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line September 2017 Technology Description: Nivolumab is a type (...) of protein designed to attach to a certain type of white blood cells called the T cells. T cells are part of the immune system needed to attack the cancer. Nivolumab acts to improve the activity of T cells, thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab is another type of protein that acts in a different way to increase the activity of T cells. If licenced, nivolumab in combination with ipilimumab will offer additional treatment option to prolong lives

NIHR Innovation Observatory2017

32. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Background Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. Methods We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per (...) kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF

NEJM2017

33. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant (...) therapy in patients with resected advanced melanoma. Methods In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were

NEJM2017

34. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator`s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator`s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial 28671856 2017 07 03 2017 07 03 1527-7755 2017 Jul 03 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized (...) , Controlled, Open-Label Phase III Trial. JCO2016718023 10.1200/JCO.2016.71.8023 Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced

EvidenceUpdates2017

37. Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H)

Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic (...) colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) August 2017 Technology Description: Nivolumab and ipilimumab is a combination therapy to treat cancer of the large bowel (colon) or back passage (rectum) – these types of cancers (bowel and colon) are also known as colorectal cancer. Metastatic colorectal cancer occurs when the cancer has spread to another part of the body; this is most commonly to the liver. A small proportion

NIHR Innovation Observatory2017

39. Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection

Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection - GOV.UK GOV.UK uses cookies to make the site simpler. Search Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection From: Published: 20 July 2017 Therapeutic area: , , and There have been reports of rejection of solid organ transplants in patients treated with nivolumab or pembrolizumab (...) . Ipilimumab (Yervoy▼) may also interfere with immunosuppressive therapy, increasing the risk of graft rejection. Contents Advice for healthcare professionals: rejection of solid organ transplants, including renal and corneal grafts, has been reported in the post-marketing setting in patients treated with programmed death receptor 1 (PD-1) inhibitors consider the benefit of treatment with nivolumab or pembrolizumab versus the risk of possible organ transplant rejection for each patient some cases

MHRA Drug Safety Update2017